Federal award
MARK CUBAN COST PLUS DRUG COMPANY, PBC
W911SR25CA006
ContractSBIR/STTR SR1
Obligated and Ceiling
- Obligated (net)
- $205,920.00
- Ceiling (potential value, not spending)
- $205,920.00
- Current value
- $205,920.00
- Gross positive obligations
- $205,920.00
Obligated is what the government has committed, net of de-obligations. The ceiling is the most the award or vehicle could ever reach; it is shown separately and never added to, or compared as, spending.
Award Details
- Recipient
- MARK CUBAN COST PLUS DRUG COMPANY, PBC · N8P7MQ937WN7
- Owner company
- Not a reviewed companyNo reviewed company owns this recipient.
- Reported parent
- MARK CUBAN COST PLUS DRUG COMPANY, PBC · N8P7MQ937WN7
- Awarding agency
- Department of War · sub-agency 2100 · office W911SR
- Funding agency
- Department of War · sub-agency 2100
- Product or service (PSC)
- AN13 · HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- Industry (NAICS)
- 541714 · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- PIID
- W911SR25CA006
- Award type code
- D
- Actions
- 1 · Jun 11, 2025 to Jun 11, 2025
- Why it is listed
- gross positive obligations of $100k or more (contracts); SBIR/STTR award
Action History1
| Date | FY | Mod | Action type | Obligation | Company in company totals |
|---|---|---|---|---|---|
| Jun 11, 2025 | FY2025 | 0 | — | $205,920.00 | — |
Newest first. Every obligation is shown as reported, including zero and negative (de-obligation) actions. Award lists belong to the company of the latest action; company totals credit each action to the company named on that row, so a note marks rows where the two differ.